Skip to main content
Erschienen in: Advances in Therapy 6/2022

30.04.2022 | Review

Iron Deficiency in Women’s Health: New Insights into Diagnosis and Treatment

verfasst von: Christina M. Moisidis-Tesch, Lee P. Shulman

Erschienen in: Advances in Therapy | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Iron deficiency (ID), with or without anemia, is commonly found worldwide and affects the health and wellbeing of pregnant and nonpregnant women. Symptoms of ID- which include fatigue, pica (ice craving), restless legs syndrome, poor concentration and work function, increased susceptibility to infection, and cardiovascular stress- can cause significant morbidity and reduced quality of life. The etiologies of iron deficiency in women are usually specific to each community. In the developing world, iron deficiency is usually associated with poor iron intake and parasitic infections, whereas in higher income regions, iron deficiency is typically the result of heavy, abnormal uterine bleeding, and pregnancy. Iron-poor diets and poor iron absorption resulting from gut disorders can also play a role. Diagnosis of iron deficiency is usually straightforward and characterized by a low ferritin level; however, the diagnosis can be challenging in women with concomitant inflammatory disorders, in which case a low percent transferrin saturation, performed after an overnight fast, can inform on the need for iron. Therapy is frequently initiated with oral iron salts; however, use of these oral regimens is commonly associated with adverse events, mostly gastrointestinal in nature, that have been shown to adversely impact compliance, continuation, and the achievement of therapeutic goals. A further impediment to the effectiveness of oral iron is its poor absorption because of comorbidity (i.e., celiac disease, gastritis, etc.), surgery (bariatric), or physiologic inhibitory mechanisms. As such, intravenous (IV) iron regimens are increasingly being used to treat ID, as such regimens have been shown to avoid the gastrointestinal adverse events commonly associated with oral regimens. Indeed, IV iron has been shown to provide adequate iron replacement in women with functional iron deficiencies as well as those with ID resulting from inflammatory disorders- patients often resistant to oral iron therapy. More recent IV iron regimens have been shown to provide iron replacement in a safe and effective manner, being associated with more salutary adverse event profiles than earlier IV iron regimens. In fact, these iron regimens can provide a complete replacement dose in a single 15–60-min visit.
Literatur
1.
Zurück zum Zitat Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.CrossRef Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.CrossRef
2.
Zurück zum Zitat Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–24.CrossRef Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–24.CrossRef
3.
Zurück zum Zitat Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015;2015:8–13.CrossRef Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015;2015:8–13.CrossRef
4.
Zurück zum Zitat Daru J, Cooper NA, Khan KS. Systematic review of randomized trials of the effect of iron supplementation on iron stores and oxygen-carrying capacity in pregnancy. Acta Obstet Gynecol Scand. 2016;95:270–9.CrossRef Daru J, Cooper NA, Khan KS. Systematic review of randomized trials of the effect of iron supplementation on iron stores and oxygen-carrying capacity in pregnancy. Acta Obstet Gynecol Scand. 2016;95:270–9.CrossRef
5.
Zurück zum Zitat Percy L, Mansour D, Fraser I. Iron deficiency and iron-deficiency anemia in women’s health. Best Pract Res Clin Obstet Gynaecol. 2017;40:55–67.CrossRef Percy L, Mansour D, Fraser I. Iron deficiency and iron-deficiency anemia in women’s health. Best Pract Res Clin Obstet Gynaecol. 2017;40:55–67.CrossRef
6.
Zurück zum Zitat Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol. 2009;15:4617–26.CrossRef Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol. 2009;15:4617–26.CrossRef
7.
Zurück zum Zitat Zhao L, Zhang X, Shen Y, et al. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16:1081–93.CrossRef Zhao L, Zhang X, Shen Y, et al. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16:1081–93.CrossRef
8.
Zurück zum Zitat Cepeda-Lopez AC, Aeberli I, Zimmermann MB. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vit Nutr Res. 2010;80:263–70.CrossRef Cepeda-Lopez AC, Aeberli I, Zimmermann MB. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vit Nutr Res. 2010;80:263–70.CrossRef
9.
Zurück zum Zitat Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105–22.CrossRef Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105–22.CrossRef
10.
Zurück zum Zitat D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48:10–5.CrossRef D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48:10–5.CrossRef
11.
Zurück zum Zitat Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Wien Med Wochenschr. 2016;166:411–23.CrossRef Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Wien Med Wochenschr. 2016;166:411–23.CrossRef
12.
Zurück zum Zitat Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and mananagement. Hematol Am Soc Hematol Educ Program. 2017;8:152–9.CrossRef Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and mananagement. Hematol Am Soc Hematol Educ Program. 2017;8:152–9.CrossRef
13.
Zurück zum Zitat Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133:43–8.CrossRef Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133:43–8.CrossRef
14.
Zurück zum Zitat Ferrara M, Coppola L, Coppola A, Caprizzi M. Iron deficiency in childhood and adolescence: retrospective review. Hematology. 2006;11:183–6.CrossRef Ferrara M, Coppola L, Coppola A, Caprizzi M. Iron deficiency in childhood and adolescence: retrospective review. Hematology. 2006;11:183–6.CrossRef
15.
Zurück zum Zitat Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:54–65.CrossRef Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:54–65.CrossRef
16.
Zurück zum Zitat Magnay JL, O’Brien S, Gerlinger C, Seitz C. A systematic review of methods to measure menstrual blood loss. BMC Women’s Health. 2018;18:142–55.CrossRef Magnay JL, O’Brien S, Gerlinger C, Seitz C. A systematic review of methods to measure menstrual blood loss. BMC Women’s Health. 2018;18:142–55.CrossRef
17.
Zurück zum Zitat Munro MG, Critchley HOD, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3–13.CrossRef Munro MG, Critchley HOD, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3–13.CrossRef
18.
Zurück zum Zitat El-Andaloussi A, Chaudhry Z, Al-Hendy A, et al. Uterine fibroids: Bridging genomic defects and chronic inflammation. Semin Reprod Med. 2017;35:494–8.CrossRef El-Andaloussi A, Chaudhry Z, Al-Hendy A, et al. Uterine fibroids: Bridging genomic defects and chronic inflammation. Semin Reprod Med. 2017;35:494–8.CrossRef
19.
Zurück zum Zitat Jimenez JM, Gache C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Haematol. 2019;142:30–6.CrossRef Jimenez JM, Gache C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Haematol. 2019;142:30–6.CrossRef
20.
Zurück zum Zitat Georgieff MK. Iron deficiency in pregnancy. Am J Obstet Gynecol. 2020;223(4):516–24.CrossRef Georgieff MK. Iron deficiency in pregnancy. Am J Obstet Gynecol. 2020;223(4):516–24.CrossRef
21.
Zurück zum Zitat Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3:a011866.CrossRef Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3:a011866.CrossRef
22.
Zurück zum Zitat Milman N. Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol. 2011;90:1247–53.CrossRef Milman N. Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol. 2011;90:1247–53.CrossRef
23.
Zurück zum Zitat Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012;91:143–54.CrossRef Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012;91:143–54.CrossRef
24.
Zurück zum Zitat Gomez-Ramirez S, Bisbe E, Shander A, et al. Management of perioperative iron deficiency anemia. Acta Haematol. 2019;142:21–9.CrossRef Gomez-Ramirez S, Bisbe E, Shander A, et al. Management of perioperative iron deficiency anemia. Acta Haematol. 2019;142:21–9.CrossRef
25.
Zurück zum Zitat Pratt JJ, Khan KS. Non-anemic iron deficiency—a disease looking looking for recognition of diagnosis: a systematic review. Eur J Haemotol. 2015;96:618–28.CrossRef Pratt JJ, Khan KS. Non-anemic iron deficiency—a disease looking looking for recognition of diagnosis: a systematic review. Eur J Haemotol. 2015;96:618–28.CrossRef
26.
Zurück zum Zitat Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306–15.PubMed Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306–15.PubMed
27.
Zurück zum Zitat Stoffel N., Cercamondi C, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; E524-E533 Stoffel N., Cercamondi C, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; E524-E533
28.
Zurück zum Zitat Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transpl. 2014;29:833–42.CrossRef Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transpl. 2014;29:833–42.CrossRef
29.
Zurück zum Zitat Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683–90.CrossRef Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683–90.CrossRef
30.
Zurück zum Zitat Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–28.CrossRef Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–28.CrossRef
32.
Zurück zum Zitat Camaschella C. Iron deficiency anemia. N Engl J Med. 2015;372:1832–43.CrossRef Camaschella C. Iron deficiency anemia. N Engl J Med. 2015;372:1832–43.CrossRef
33.
Zurück zum Zitat Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16–30.CrossRef Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16–30.CrossRef
34.
Zurück zum Zitat Kim YH, Ching HH, Kang S-B, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009;121:37–41.CrossRef Kim YH, Ching HH, Kang S-B, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009;121:37–41.CrossRef
35.
Zurück zum Zitat Lee S, Ryu KJ, Lee ES, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: an open-label, multicenter, randomized study. J Obstet Gynaecol Res. 2019;45:858–64.CrossRef Lee S, Ryu KJ, Lee ES, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: an open-label, multicenter, randomized study. J Obstet Gynaecol Res. 2019;45:858–64.CrossRef
36.
Zurück zum Zitat Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–14.CrossRef Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–14.CrossRef
37.
Zurück zum Zitat Wolf M, Auerbach M, Kalra PA. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96:E11–5.CrossRef Wolf M, Auerbach M, Kalra PA. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96:E11–5.CrossRef
38.
Zurück zum Zitat Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8.CrossRef Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8.CrossRef
39.
Zurück zum Zitat DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142:8–12.CrossRef DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142:8–12.CrossRef
40.
Zurück zum Zitat Freidman AJ, Shander A, Martin SR, et al. Iron deficiency anemia in women: a practical guide to detection, diagnosis, and treatment. Obstet Gynecol Surv. 2015;70:342–53.CrossRef Freidman AJ, Shander A, Martin SR, et al. Iron deficiency anemia in women: a practical guide to detection, diagnosis, and treatment. Obstet Gynecol Surv. 2015;70:342–53.CrossRef
41.
Zurück zum Zitat DeLoughery TG. Iron deficiency anemia. Med Clin North Am. 2017;101:319–32.CrossRef DeLoughery TG. Iron deficiency anemia. Med Clin North Am. 2017;101:319–32.CrossRef
42.
Zurück zum Zitat Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12–23.CrossRef Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12–23.CrossRef
Metadaten
Titel
Iron Deficiency in Women’s Health: New Insights into Diagnosis and Treatment
verfasst von
Christina M. Moisidis-Tesch
Lee P. Shulman
Publikationsdatum
30.04.2022
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 6/2022
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-022-02157-7

Weitere Artikel der Ausgabe 6/2022

Advances in Therapy 6/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.